Objective To investigate the effect of mean - dose Lovastatin in the treatment of essential hyperlipidemia. Methods 91 cases were randomly single- blindly assigned into tested(n = 61) and contral group (n = 30), Besides the controlling of diet, patients in the tested were treated with Lovastatin 20 rng, orally,qn;while subjects in the control group with Elastase 600mg tid, for the course of 8 weeks. Results After 8 weeks of treatment, compared with itself in the tested group, the levels of TC、 TG、 LDL - C、 VLDL - C decreased from 6.86 ± 0.99(mmol/L) to 4.61 ±0.82、2.04± 1.04 to 1.31 ±0.63、5.17 ± 1.01 to 3.00±0.81、0.46 ± 0.42 to 0.27 ± 0.13 respectively, all P ＜ 0.001; HDL- C rised from 1.19 ± 0.38 to 1.32 ± 0.39, P ＜ 0.05; AI decreased from 4.76 to 2.49. There were significant differences(P ＜ 0. 001 ) between the groups. There were no obvious influences on functions of liver and kidney, level of blood sugar. Conclusion 20 mg/d for Lovastatin is a proper dose, the efficacy of regulating lipicls is ideal and all - rounded, side effectsare relatively slight.%目的研究中剂量洛伐他汀对原发性高脂血症的治疗效果。方法按照随机单盲对照法把患者分为2组，在控制饮食的基础上，治疗组61例口服洛伐他汀每晚20mg，对照组口服弹性酶600ag，tid，均8周为1个疗程。结果洛伐他汀组治疗前后血脂(mmol/L)水平自身对比：TC、TG、LDL-C、VLDL-C分别从6.86±0.99、2.04±1.04、5.17±1.01、0.46±0.42降至4.61±0.82、1.31±0.63、3.00±0.81及0.27±0.13(均P＜0.001)，HDL-C从1.19±0.38升至1.32±0.39(P＜0.05)，致粥样硬化指数从4.76降至2.49。弹性酶组，代(mmol/L)从6.15±0.76降至5.77±0.80(P＜0.01)，LDL-C(mmol/L)从4.54±0.76降至4.21±0.78(P＜0.05)，而对TG、VLDL-C、HDL-C及致粥样硬化指数无明显影响。两组调脂疗效比较：洛伐他汀降低TC、TG的总有效率分别为96.7％和75.4％，升高HDL-C总有效率63.9％；而弹性酶降低TC、TG的总有效率均为36.7％，升高HDL-C总有效率为23.3％，两组相比均P＜0.00l。两药对肝、肾功能及血糖无明显影响。结论洛伐他汀每日20mg，剂量适宜，调脂作用理想而全面，疗效可靠，副作用轻微。
展开▼
